Thursday, August 11, 2022


Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma

Latest Posts

New Study Highlights Superior Efficacy of At-home Dry EEG assessment Compared to Lab-based Monitoring

Results indicate that easy-to-use task-driven EEG can yield clinical-grade data in large-scale, real-world investigations in neuroscience with extremely high adherence rates.

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

“We are excited to further advance the development of GDA-201, a NAM-enabled natural killer (NK) cell therapy candidate which we believe has the potential to be a new readily available, cryopreserved treatment option for cancer patients with relapsed/refractory lymphoma,” said Ronit Simantov, M.D., chief medical and scientific officer of Gamida Cell.

Akadeum Life Sciences Announces New Dead Cell Removal Kit Using Microbubble Technology

Akadeum Life Sciences advises that the new buoyant separation method creates a more effective way for researchers to use valuable samples with a higher retention rate of viable cells than current magnetic techniques.

Bio-Rad Extends Range of StarBright Violet and UltraViolet Dyes for Multiplex Flow Cytometry

StarBright Violet 760, StarBright UltraViolet 575, and StarBright UltraViolet 605 dyes conjugated to highly validated antibodies for multicolor panel design in immunology research.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its MolDX program, has expanded coverage of the clonoSEQ® Assay to include monitoring minimal residual disease (MRD) in Medicare patients with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL).

This coverage determination is the first for clonoSEQ to include the assessment of MRD based on circulating tumor DNA (ctDNA), fragments of DNA released into the blood from lysed cancer cells.

MRD refers to the remaining number of cancer cells that may be present in a patient’s body during and after treatment and that may eventually lead to recurrence of the disease. MRD testing is a simple blood test performed at multiple timepoints throughout a patient’s cancer journey to assess prognosis, determine response to treatment, detect relapse, and inform care. MRD assessment in DLBCL utilizes ctDNA measured in peripheral blood to give oncologists a better understanding of which patients are at high-risk for recurrence and provide them with information to create a more precise treatment plan for each patient.

“We’ve advanced therapy for large B-cell lymphomas significantly in recent years; however, a considerable unmet need for highly specific, precise monitoring of disease progression during and after treatment remains,” said Frederick Locke, M.D., chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center”

He added, “Measurement of ctDNA to assess MRD provides additional information that can complement or improve upon insights from imaging and that can help inform clinical management.”

The updated coverage policy expands DLBCL patient access to clonoSEQ MRD testing, as approximately 75% of actively treated DLBCL patients are Medicare aged. The policy is effective immediately and extends to all DLBCL patients, regardless of line of therapy, treatment regimen, or testing timepoint. clonoSEQ testing for DLBCL patients is currently available for clinical use as a laboratory-developed test (LDT) performed at Adaptive’s CLIA-certified lab in Seattle, WA. clonoSEQ ctDNA-based MRD testing in DLBCL has also been approved by New York State’s Clinical Laboratory Evaluation Program (CLEP).

“We believe clonoSEQ raises the bar for disease monitoring in DLBCL patients. Recent studies have shown that MRD assessment with clonoSEQ early post CAR-T treatment can be more informative than PET-CT in identifying patients who were at high risk for relapse,” said Nitin Sood, chief commercial officer, MRD, Adaptive Biotechnologies. “The Medicare coverage decision provides greater access to clonoSEQ and acknowledges the mounting evidence for implementing routine clonoSEQ MRD assessment in DLBCL.”

This coverage expansion adds to existing Medicare coverage for clonoSEQ in multiple myeloma, chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (ALL). Medicare coverage for clonoSEQ in these indications is aligned with clinical practice guidelines which support assessing MRD at multiple time points throughout therapy to monitor treatment response and help predict patient outcomes.

About the clonoSEQ Assay: The clonoSEQ Assay is the first and only FDA-cleared in vitro diagnostic (IVD) test service to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). MRD refers to the small number of cancer cells that can stay in the body during and after treatment.

The clonoSEQ Assay leverages Adaptive Biotechnologies’ proprietary immune medicine platform to identify and quantify specific DNA sequences found in malignant cells, allowing clinicians to assess and monitor MRD during and after treatment. The assay provides standardized, accurate and sensitive measurement of MRD that allows physicians to predict patient outcomes, assess response to therapy over time, monitor patients during remission and predict potential relapse. Clinical practice guidelines in hematological malignancies recognize that MRD status is a reliable indicator of clinical outcomes and response to therapy, and clinical outcomes have been shown to be strongly associated with MRD levels measured by the clonoSEQ Assay in patients diagnosed with CLL, MM and ALL.

For important information about the FDA-cleared uses of clonoSEQ, including the full intended use, limitations, and detailed performance characteristics, please visit

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine